Discontinuation report CYTARABINE INJECTION
Report ID | 94589 |
Drug Identification Number | 02126656 |
Brand name | CYTARABINE INJECTION |
Common or Proper name | CYTARABINE INJECTION |
Company Name | PFIZER CANADA ULC |
Market Status | MARKETED |
Active Ingredient(s) | CYTARABINE |
Strength(s) | 100MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRATHECAL INTRAVENOUS SUBCUTANEOUS |
Packaging size | 10mL vial |
ATC code | L01BC |
ATC description | ANTIMETABOLITES |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2019-09-24 |
Remaining supply date | 2019-09-24 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | 1mL and 20mL presentations remain available. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2019-09-24 | English | Compare |
v2 | 2019-09-24 | French | Compare |
v3 | 2019-09-25 | English | Compare |
Showing 1 to 3 of 3